NCT06723652View on ClinicalTrials.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 13, 2025

Primary Completion Date

August 25, 2025

Study Completion Date

December 31, 2025

Conditions

Homozygous Familial Hypercholesterolemia

Interventions

DRUG

SHR-1918

six administration

DRUG

SHR-1918 placebo

SHR-1918 placebo three administration+SHR-1918 three administration

Trial Locations (1)

410000

The Second Xiangya Hospital of Central South University Hospital, Changsha

All Listed Sponsors

lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY

NCT06723652 - A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | Biotech Hunter | Biotech Hunter